MDxHealth Shareholder Transparency Declaration
10 Octobre 2019 - 7:00AM
IRVINE, CA, and HERSTAL,
BELGIUM – 10 October 2019 – MDxHealth SA (Euronext
Brussels: MDXH) (the “Company” or
"MDxHealth"), a commercial-stage innovative
molecular diagnostics company, announced that it received the
following notification, dated 7 October 2019, of a significant
shareholding in accordance with the Belgian Act of 2 May 2007 on
the disclosure of important participations in issuers of which
shares are admitted to trading on a regulated market and
regarding miscellaneous provisions.
Valiance Asset Management Limited notified
MDxHealth of the acquisition, through different entities, of voting
rights attached to securities in MDxHealth, as a result of which,
on 1 October 2019, its aggregate participation of these entities in
MDxHealth exceeded the threshold of 15% of the outstanding shares
and voting rights of MDxHealth. Notably, it follows from the
notification by Valiance Asset Management Limited, acting as parent
undertaking or controlling person, that an aggregate of 11,159,202
shares of MDxHealth, representing 15.82% of the 70,528,525
outstanding shares and voting rights of MDxHealth, is held through
the following entities: TopMDx Ltd (holding 5,358,464 shares, being
7.60% of the outstanding shares and voting rights), Valiance Life
Sciences Growth Investments SICAV-SIF (holding 5,565,058 shares,
being 7.89% of the outstanding shares and voting rights), and
Valiance Holdings Limited (holding 235,680 shares, being 0.33% of
the outstanding shares and voting rights). The notification also
stated that Valiance Holdings Limited is a Guernsey company within
the Valiance corporate structure, that Valiance Life Sciences
Growth Investment Fund SICAV-SIF is a Luxembourg fund with multiple
external investors, that TopMDx Ltd is an exempted closed-ended
fund registered in BVI with multiple external investors, and that
Valiance Asset Management Limited is investment manager and makes
the investment decisions for each of these entities and therefore
exercises the control over the investment.
For further information, reference is made to
the information published on MDxHealth's website
(http://www.mdxhealth.com/investors/shareholder-information).
About MDxHealth®
MDxHealth is a multinational healthcare company
that provides actionable molecular diagnostic information to
personalize the diagnosis and treatment of cancer. The Company's
tests are based on proprietary genetic, epigenetic (methylation)
and other molecular technologies and assist physicians with the
diagnosis of urologic cancers, prognosis of recurrence risk, and
prediction of response to a specific therapy. The Company's
European headquarters are in Herstal, Belgium, with laboratory
operations in Nijmegen, The Netherlands, and US headquarters and
laboratory operations based in Irvine, California. For more
information, visit mdxhealth.com and follow us on social media at:
twitter, facebook and linkedin.
For more information:
Amber Fennell, Chris Welsh, Nicholas Brown Consilium Strategic
CommunicationsUK: +44 20 3709 5700mdxhealth@consilium-comms.com
Important InformationThe MDxHealth logo, MDxHealth, ConfirmMDx
and SelectMDx are trademarks or registered trademarks of MDxHealth
SA (the “Company” or “MDxHealth”). All other trademarks and service
marks are property of their respective owners.
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024